Published in J Acquir Immune Defic Syndr on December 01, 2013
The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population. BMC Public Health (2016) 0.75
Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss. Pharmacoeconomics (2017) 0.75
The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines (Basel) (2017) 0.75
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther (2000) 3.14
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis (2009) 1.79
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS (2007) 1.51
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother (2007) 1.27
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr (2009) 1.19
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther (2009) 1.15
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr (2007) 1.12
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med (2000) 1.11
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2008) 1.09
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS (2007) 1.03
Determinants of the cost of health services used by veterans with HIV. Med Care (2011) 0.95
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis (2013) 0.94
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. J Acquir Immune Defic Syndr (2007) 0.92
Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr (2009) 0.91
Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis (2006) 0.88
A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. HIV Clin Trials (2010) 0.85
Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Med (2009) 0.84
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics (2010) 0.84
US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics (2010) 0.83
Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials (2008) 0.83
Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. PLoS One (2011) 0.82
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Cost Eff Resour Alloc (2007) 0.81
Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics (2010) 0.81
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics (2010) 0.81
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS (2012) 0.81
Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clin Trials (2009) 0.80
Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial. Med Decis Making (2011) 0.79
Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico. Value Health (2010) 0.78
Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain. AIDS Res Hum Retroviruses (2009) 0.78
Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. Clin Ther (2010) 0.77
Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med (2007) 9.88
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health (2009) 9.79
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA (2006) 9.36
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med (2005) 7.46
Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA (2009) 6.11
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Effect of home testing of international normalized ratio on clinical events. N Engl J Med (2010) 5.36
Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med (2010) 5.14
Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med (2012) 4.62
Systematic review: surveillance systems for early detection of bioterrorism-related diseases. Ann Intern Med (2004) 4.58
Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health (2009) 4.29
Quality improvement strategies for hypertension management: a systematic review. Med Care (2006) 4.29
Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med (2008) 4.28
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med (2003) 3.88
Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med (2013) 3.51
Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976) (2009) 3.45
Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med (2011) 3.36
Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart (2011) 3.29
A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet (2002) 3.26
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med (2007) 3.17
Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2007) 3.14
Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med (2007) 3.10
Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Clin Infect Dis (2008) 3.10
Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med (2007) 3.03
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med (2009) 3.03
Systematic review: elective induction of labor versus expectant management of pregnancy. Ann Intern Med (2009) 3.01
HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med (2010) 3.00
Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med (2008) 2.96
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med (2004) 2.89
Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med (2006) 2.80
Incidence of fires and related injuries after giving out free smoke alarms: cluster randomised controlled trial. BMJ (2002) 2.77
Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from theAmerican College of Physicians. Ann Intern Med (2014) 2.75
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 2.69
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2007) 2.69
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med (2014) 2.69
Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med (2011) 2.68
Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy (2007) 2.66
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl (2007) 2.61
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest (2007) 2.57
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ (2005) 2.52
Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev (2003) 2.52
Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. Ann Intern Med (2006) 2.49
Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics (2006) 2.43
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Diagnostic imaging for low back pain: advice for high-value health care from the American College of Physicians. Ann Intern Med (2011) 2.29
Leaving hospital against medical advice among HIV-positive patients. CMAJ (2002) 2.24
Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation (2006) 2.24
Cost-effectiveness of elective induction of labor at 41 weeks in nulliparous women. Am J Obstet Gynecol (2010) 2.22
Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum (2005) 2.20
Long-term (10-year) mortality of younger previously healthy patients with severe sepsis/septic shock is worse than that of patients with nonseptic critical illness and of the general population. Crit Care Med (2014) 2.19
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ (2003) 2.18
Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2004) 2.12
Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res (2011) 2.11
Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics (2006) 2.10
Safety and efficiency of emergency department assessment of chest discomfort. CMAJ (2004) 2.09
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med (2005) 2.07
Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med (2013) 2.05
Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS (2010) 2.04
Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation (2010) 2.00
Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.98
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis (2014) 1.94
Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy (2009) 1.94
Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care (2005) 1.94
Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.92
Acupuncture and counselling for depression in primary care: a randomised controlled trial. PLoS Med (2013) 1.90
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS (2007) 1.85
Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.83
Evaluation of primary care patients with chronic stable angina: guidelines from the American College of Physicians. Ann Intern Med (2004) 1.78
Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ (2005) 1.78
Prevalence of working smoke alarms in local authority inner city housing: randomised controlled trial. BMJ (2002) 1.77
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malar J (2011) 1.76
The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med (2010) 1.76
Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med (2007) 1.75
Cost-effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States. Ann Emerg Med (2013) 1.74
What do international pharmacoeconomic guidelines say about economic data transferability? Value Health (2010) 1.74
Intensive care unit admission has minimal impact on long-term mortality. Crit Care Med (2002) 1.73
Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med (2007) 1.72
Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA (2010) 1.71
Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation (2013) 1.71
Validating smoking data from the Veteran's Affairs Health Factors dataset, an electronic data source. Nicotine Tob Res (2011) 1.69
Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med (2005) 1.69
Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med (2009) 1.68
Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg Infect Dis (2016) 1.68